|Type||Public KK (TYO: 4568)|
|Founded||2005 (by merger)|
|Key people||Takashi Shoda, Chairman
Joji Nakayama, President & CEO
$11.655 billion USD(¥ 967.4 billion JPY) (FY 2010)
|Net income||¥ 131,800 million JPY (FY 2010)|
30,488 (2010)products = Pharmaceutical products
Daiichi Sankyo Co., Ltd. (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 970 billion in revenue in 2010 and is currently ranked number 17 in world sales. Its headquarter is based in Tokyo. The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India. Daiichi Sankyo is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. with total sales of USD 2.7 billion.
Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.
Daiichi Sankyo Co., Ltd. is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
In 2009, the highly respected magazine R&D Direction honoured Daiichi Sankyo with its "Best Cardiovascular Pipeline Award".
Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社 Sankyō Kabushiki Kaisha ) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha ), which were century-old pharmaceutical companies based in Japan.
On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkeley, California-based pharmaceutical start-up company for $805 Million and an additional $130 Million in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (Roche licensed) drug. 
Products of Daiichi Sankyo Group 
- Benicar (olmesartan medoxomil)
- Mevalotin (pravastatin)
- Loxonin (loxoprofen)
- Olmetec (olmesartan)
- WelChol (colesevelam HCl)
- Effient (Prasugrel) (co-marketed with Eli Lilly and Company)
- win bp piramal (olmesartan medoxomil)
Daiichi Pharmaceutical 
- Cravit (levofloxacin)
- Evoxac (cevimeline)
- FloxinOtic (ofloxacin)
- Gracevit (sitafloxacin, only sold in Japan)
Pipeline candidates 
Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:
- CS-011 (rivoglitazone) — Type 2 Diabetes
- CS-1008 — Oncology
- CS-8958 (Laninamivir) — Influenza
- DU-176b (Edoxaban) — Venous thromboembolism
- SUN-11031 — Cachexia
|This article about a Japanese corporation– or company–related topic is a stub. You can help Wikipedia by expanding it.|
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|